Medicine and Dentistry
Activated Prothrombin Complex
18%
Acute Lymphoblastic Leukemia
20%
Adverse Event
9%
Anticoagulant Therapy
18%
Bleeding
64%
Bleeding Diathesis
18%
Bleeding Disorder
41%
Blood Clotting Factor
9%
Blood Clotting Factor 8
12%
Blood Clotting Factor 8 Inhibitor
12%
Blood Stasis
35%
Cancer
12%
Central Venous Catheter
9%
Ciclonicate
15%
Cohort Effect
9%
Delayed Diagnosis
10%
Disease
37%
Emicizumab
69%
Ex Vivo
17%
Factor XI
16%
Glanzmann's Thrombasthenia
24%
Haemophilia
51%
Haemophilia A
100%
Haemophilia B
24%
Hematologic Malignancy
22%
Hemostat
50%
Immunological Tolerance
18%
Invasive Procedure
12%
Malignant Neoplasm
29%
Mucormycosis
16%
Neonatal Alloimmune Thrombocytopenia
24%
Neonate
12%
Patient with Hemophilia
33%
Pediatric Hematology
10%
Pediatrics
97%
Pediatrics Patient
39%
Phlebothrombosis
16%
Platelet
12%
Prospective Study
18%
Retrospective Study
12%
Substitution Therapy
22%
Surgery
17%
Surgical Technique
15%
Symptom
16%
Thrombin
61%
Thrombocytopenia
17%
Thromboembolism
12%
Thrombophilia
18%
Thrombosis
46%
Venous Thromboembolism
17%
Keyphrases
Acute Lymphoblastic Leukemia
20%
Anticoagulant Treatment
16%
Bleeding
34%
Bleeding Complications
18%
Bleeding Episodes
20%
Bleeding Tendency
15%
Cancer-associated Thrombosis
19%
Central Venous Line
15%
Children with Cancer
16%
Emicizumab
77%
Epidemiology
15%
Etiological Factors
14%
Etiology
18%
Factor VIII (FVIII)
20%
Factor XI Deficiency
16%
FEIBA
14%
FVIII Inhibitors
21%
Glanzmann Thrombasthenia
24%
Haemophilia with Inhibitors
13%
Hematological Malignancies
25%
Hemophilia
99%
Hemophilia A Carrier
16%
Hemophilia B
20%
Hemostasis
37%
Hemostatic System
18%
Inherited Thrombophilia
16%
Laboratory Assays
16%
Neonatal Alloimmune Thrombocytopenia
24%
Neonate
18%
Pediatric
75%
Pediatric Patients
48%
Pediatric Population
29%
Platelets
15%
Population-based Study
13%
Rare Bleeding Disorders
29%
Recombinant Activated Factor VII (rFVIIa)
26%
Replacement Therapy
13%
Risk Factors
21%
Severe Haemophilia A
25%
Surgical Procedures
16%
Thrombin Generation
72%
Thrombocytopenia
15%
Thromboembolism
18%
Thrombophilia
16%
Thrombosis
27%
Thrombosis Risk
19%
Thrombotic Complications
15%
Treatment Options
19%
Venous Thromboembolism
26%
Von Willebrand Disease
14%
